Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Marco Kessler"'
Autor:
Kimberly Chambert, Marco Kessler, Yan Chen, Nisha Perez, Mark G. Currie, Maria D. Ribadeneira
Publikováno v:
Journal of Clinical Gastroenterology. 56:218-223
Goals The aim was to measure bile acids in human saliva using a sensitive ultraperformance liquid chromatography tandem mass spectrometry analysis method to distinguish quantitative differences in refractory gastroesophageal reflux disease (GERD) pat
Autor:
Marco Kessler, Jaime L. Masferrer, Nicholas Robert Perl, Sylvie G. Bernier, Iris Navarro, Gerhard Hannig, W. Daniel Stamer, Renee Sarno, Pei Ge
Publikováno v:
Investigative Ophthalmology & Visual Science
Purpose The nitric oxide (NO)-cyclic guanosine-3',5'-monophosphate (cGMP) pathway regulates aqueous humor outflow and therefore, intraocular pressure. We investigated the pharmacologic effects of the soluble guanylate cyclase (sGC) stimulator IWP-953
Publikováno v:
Gastroenterology. 158:S-313
Publikováno v:
Gastroenterology. 158:S-314
Autor:
Marco Kessler, Robert Solinga, Boris Tchernychev, Inmaculada Silos-Santiago, Nadia A. Ameen, David Arthur, Md. Kaimul Ahsan, Gerhard Hannig, Cristina I. Linde
Publikováno v:
Physiological Reports
The transmembrane receptor guanylyl cyclase‐C (GC‐C), expressed on enterocytes along the intestine, is the molecular target of the GC‐C agonist peptide linaclotide, an FDA‐approved drug for treatment of adult patients with Irritable Bowel Syn
Autor:
Robert Solinga, Jenny Tobin, Alexander P. Bryant, Marco Kessler, Mark G. Currie, Gerhard Hannig, James Wakefield, Caroline B. Kurtz, Wilmin Bartolini, Robert W. Busby, Carolyn S. Higgins
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 344:196-206
Linaclotide, a potent guanylate cyclase C agonist, is a therapeutic peptide approved in the United States for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. We present for the first time the metabolis
Publikováno v:
Gastroenterology. 154:S-193
Autor:
Marco Kessler, Etchell A. Cordero, Robert W. Busby, Wilmin Bartolini, Gerhard Hannig, Mark G. Currie, Caroline B. Kurtz, Jenny Tobin, Alexander P. Bryant, Shalina Mahajan-Miklos, Robert Solinga, Christine M. Pierce, Mitchell B. Cohen
Publikováno v:
Life Sciences. 86:760-765
Aims Linaclotide is an orally administered 14-amino acid peptide being developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation. We determined the stability of linaclotide in the intestine, mea
Publikováno v:
Linköping Electronic Conference Proceedings.
Due to different requirements for simulation during the design process of an electric drive system, investigations were carried out to supply models of different stages with consistent sets of parameters. Therefore physical models of the Modelica Sta
Autor:
Etchell A. Cordero, Robert Solinga, Mark G. Currie, Robert W. Busby, Caroline B. Kurtz, Marco Kessler, Li Jing Sun, Shalina Mahajan-Miklos, Wilmin Bartolini, Alexander P. Bryant, Gerhard Hannig, Christine M. Pierce, Jenny Tobin
Publikováno v:
European journal of pharmacology. 649(1-3)
Linaclotide is a first-in-class, orally administered 14-amino acid peptide that is in development for the treatment of irritable bowel syndrome with constipation and chronic constipation. We have characterized the solution structure of linaclotide, t